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1. Introduction
  Diabetes mellitus (DM) is a group of metabolic disorder 
characterized by elevated blood glucose level resulting 
from the defects in insulin secretion, insulin action, or 
both[1]. The world prevalence of diabetes among adults 
is expected to be 6.4%, affecting 285 million adults, in 
2010, and will increase to 7.7% ie. about 439 million adults 
by 2030. Between 2010 and 2030, there will be a 69% 
increase in numbers of adults with diabetes in developing 
countries and a 20% increase in developed countries[2]. 
However, among the two major types of diabetes ie. type 1 
and type 2, type 2 DM is the commonest form of diabetes 
constituting 90%-95% of the diabetic population. It was 
also documented that the number of people diagnosed 
with type 2 DM globally is estimated to be at 2%-3% of 
the world population and is rising at a rate of 4%-5% per 
year[3]. Currently available oral hypoglycemic drugs for 
the treatment of DM have characteristic profile of adverse 
effects. Hence, research is focused to screen the medicinal 
plant that are used traditionally for the treatment of DM to 
find a newer lead drug molecule from phytoconstituents 
with more potential and lesser side effects than the existing 
hypoglycemic agents[4]. Many review articles research paper 
appeared in the journals and book showed that many plant 
used in the traditional system of medicine for the treatment 
of DM proved to be scientifically effective[5,6].
  Alangium lamarckii Thwaites (Syn. A. salviifolium)(A. 
lamarckii) belongs to family Alangiaceae is found commonly 
in tropical forest of South India and occasionally grown in 
garden. The root, root bark, seeds and leaves of the plant 
is used in Indian system of medicine. The root and root 
bark of the plant are used as antihelmenthic and purgative, 
whereas fruits are used as cooling, nutritive and tonic. 
Leaves of A. lamarckii are useful for curing diabetes[7,8]. 
Decoction of bark has been used as an emetic in India[9]. 
Methanol extract of A. salviifolium flowers have shown to 
have antibacterial activity against both gram-positive and 
gram-negative bacteria[10]. Methanolic extract of root of A. 
salviifolium have shown analgesic and anti-inflammatory 
activities in albino mice[11]. The lyophilized powder extract 
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of pulverized wood of A. salviifolium showed good antifungal 
activity against Candida albicans[12]. Ethanolic extract 
obtained from leaves of A. salviifolium have showed wound 
healing potential in rats by incision, excision; dead space 
(granulation) wound models[13]. Alangium A and B from 
root bark and akoline, lamarkine, alangine, akharkantine 
from bark, have been reported[14]. The present study was 
undertaken to scientifically evaluate the antidiabetic 
potential of alcoholic extract of A. lamarckii leaves in type 2 
diabetic rats.
2. Materials and methods
2.1. Chemicals
  Streptozotocin (STZ) was obtained from Sigma-Aldrich 
Co., St. Louis, USA. Solvents were purchased from SD Fine 
Chemicals Ltd., Mumbai, India. All the chemicals used 
were of analytical grade. For estimation of blood glucose 
and other biochemical tests, kits were obtained from Span 
diagnostic Ltd, India.
2.2. Plant material 
  The leaves of A. lamarckii Thwaites were collected from 
Panakudi, Tirunelveli District in the month of July 2009, 
identified and authenticated by Prof. V. Chelladurai, 
Research Botanist (Retd.), Palayamkottai, Tamilnadu, 
India. For future reference the voucher specimen (Specimen 
number-COG/AL/09) and the prepared herbarium was 
deposited at the Department of Pharmaceutics, Banaras 
Hindu University, Varanasi (U.P), India.
2.3. Preparation of extract
  The leaves of A. lamarckii were freed from foreign 
matter[15], dried under shade and were crushed to coarse 
powder from where 250 g was subjected to extraction by cold 
maceration method using 2 L ethanol (95%) as an extraction 
menustrum for 7 days. The alcoholic extract of A. lamarckii 
(AAL) was concentrated under reduced pressure to dryness. 
The yield of alcoholic extracts was 11.2% w/w. Extract was 
preserved in a desiccator till further use.
2.4. Animals
  Healthy male albino rats of Charles foster strain (150-200 g)
were obtained from the Central Animal House (Reg. No. 
542/02/ab/CPCSEA), Banaras Hindu University, Varanasi, 
India. All animals were maintained under standard 
environment conditions (22-28℃, 60%-70% relative 
humidity, 12 h dark : light cycle) and were fed with standard 
rat feed (Mona Laboratory Animal Feeds, Raman Dairy 
Vikas Udyog, India) and  allowed to drink water ad libitum. 
The animals were allowed to acclimatize to the environment 
for 7 days before the commencement of experiments. All 
the experimental procedures conducted after the approval 
of ethical committee (No. Dean/2009-10/579) and were in 
strict accordance with institutional animal ethical committee 
guidelines for the care and use of laboratory animals.
2.5. Acute toxicity study
  Acute oral toxicity study was performed as per Organization 
for Economic Co-operation and Development guidelines 
425. Nulliparous and non pregenant healthy female rats were 
used for this study. After the oral administration of AAL in 
overnight fasted rats, animals were observed individually 
for 48 h and their behavioral and neurological changes 
such as tremors, convulsions, salivation, diarrhoea, sleep, 
lacrimation and feeding behavior in drug treated rats were 
observed for sign of acute toxicity[16].
2.6. Normoglycemic study
  Fasted rats were divided into 4 groups consisting of 6 
animals in each group. Group Ⅰ rats received vehicle only. 
Group Ⅱ and Ⅲ rats received AAL at the doses of 250 and 
500 mg/kg, p.o. suspended in CMC (0.5% w/v) in a single 
dose. Group Ⅳ received Glibenclamide (10 mg/kg, p.o.) as 
standard drug dissolved in distilled water. Blood samples 
were collected by retro-orbital puncture method just 
prior to and at 1, 2, 4 and 6 h after dosing and glucose was 
estimated[17].
2.7. Oral glucose tolerance test
  Overnight fasted animals were separated in 4 groups of 
6 rats each. Animals of all groups were administered with 
glucose (2 g/kg) orally by means of gastric intubation. 
Animal in group second and third were treated orally with 
ethanolic extract at a dose of 250 and 500 mg/kg, p.o. and 
group fourth (positive control) with glibenclamide (10 mg/
kg), 30 min before the oral administration of glucose orally. 
Control animals were administered with equal volume of 
water only, blood sample were withdrawn from the retro 
orbital plexus of eye of each animals just after oral glucose 
administration (0, 30, 60, 90 and 120 min) after glucose 
challenge.
2.8. Induction of STZ-nicotinamide induce diabetes in rats
  Diabetes was induced in overnight fasted rats by single 
intraperiteoneal injection (i.p.) of STZ (65 mg/kg) prepared 
in citrate buffer pH 4.5, 15 min after the i.p. injection 
of nicotinamide (110 mg/kg) prepared in normal saline 
according to previously described method[18]. Rats with 
marked hyperglycemia (fasted blood glucose level greater 
than 200 mg/dL) after one week of administration of STZ were 
selected and used for this study.
  The rats were divided into five groups of six rats in each 
group:
Group Ⅰ (NC): Normal rats treated with vehicle alone;
Group Ⅱ (DC): Diabetic rats treated with vehicle alone;
Group Ⅲ (D+AAL 250): Diabetic rats treated with AAL at the 
dose of 250 mg/kg;
Group Ⅳ (D+AAL 500): Diabetic rats treated with AAL at the 
dose of 500 mg/kg;
GroupⅤ(D+Glib 10): Diabetic rats treated with glibenclamide 
at the dose of 10 mg/kg;
  All rats except normal and diabetic control group were 
administered single dose of drug (orally) daily for 14 days. 
Normal and diabetic control group rat received equal 
volume of vehicle only. The day of administration of first 
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dose was considered the zero day of treatment. Blood 
samples were collected by retro-orbital plexus of eye under 
light ether anesthesia and fasting blood glucose levels were 
determined by glucose oxidase method on day 0th, 7th, and 
14th with commercially available biochemical kit. Body 
weight of rats was also taken on day 0th and 14th. On 14th 
day, plasma lipid profiles were estimated using biochemical 
kits and liver glycogen levels were estimated using anthrone 
reagent[19]. Lipid peroxidation in liver was estimated by 
measuring thiobarbituric acid reactive substances (TBARS) 
using the methods of Nehius and Samuelson[20]. Catalase 
(CAT) was estimated by the method of Sinha[21] and the 
activity of superoxide dismutase (SOD) was assayed by 
the method of Kakkar et al[22]. Protein content in tissue 
homogenate was measured by the method of Lowry et al[23].
2.9. Statistical analysis
  Values were represented as mean 依 standard error of mean 
(SEM). Two-ways ANOVA followed by Bonferroni post test 
was performed for normoglycemic, oral glucose tolerance 
test and evaluation of blood glucose of STZ-nicotinamide 
induced diabetic rats. One-way ANOVA followed by Tukey’s 
multiple comparison test was applied for the statistical 
analysis of the rest of parameters. GraphPad Prism (version 
4) software was used for all statistical analysis. P values 
<0.05 were considered significant.
3. Results
  Acute toxicity study showed that AAL upto 5 000 mg/
kg body weight did not show any sign of acute toxicity 
and was found to be safe. In normoglycemic study, AAL 
at two doses ie. 250 and 500 mg/kg orally did not reduce 
the plasma glucose in rats. However, the rats treated with 
glibenclamide, 10 mg/kg showed a marked reduction in 
glucose level (P<0.001) as compared to control 1 h after 
its administration (Figure 1). Administration of AAL at two 
doses 250 and 500 mg/kg orally half an hour prior to glucose 
load showed improved glucose tolerance in normal rats. 
Maximum effect was observed 30-60 min after the glucose 
load in rat treated with AAL 250 mg/kg (P<0.001) while in 
case of AAL 500 mg/kg, maximum effect was observed 30-90 min
after glucose load (P<0.001). Glibenclamide (10 mg/kg) 
showed a significant decrease in plasma glucose level when 
compared to vehicle control animals (Figure 2). 
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Figure 1. Effect of AAL on normal rats. 
*P<0.001 compared to normal control (Two-way ANOVA followed by 
Bonferroni post test).
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Figure 2. Effect AAL on oral glucose tolerance test in normal rats. 
*P<0.05, **P<0.001compared to normal control (Two-way ANOVA 
followed by Bonferroni post test).
  Induction of diabetes in the experimental rats was 
confirmed by the presence of a high fasting plasma glucose 
level estimated on 0th day of administration of AAL. The 
effect of AAL on fasting plasma glucose level of STZ-
nicotinamide induced animals are presented in Figure 
3. The one week treatment of diabetic rats with 250 mg/
kg orally did not significantly reduced the plasma glucose 
level (P>0.05), however continuation of treatment upto 
two week significantly reduced the plasma glucose level. 
Administration of AAL 500 mg/kg orally showed significant 
lowering of fasting plasma glucose level (P<0.001) in diabetic 
rats and was comparable to standard drug treated rats. 
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Figure 3. Effect of AAL on the blood glucose level of streptozotocin-
nicotinamide induced diabetic rats. 
△P<0.001compared to normal control, *P<0.001compared  to diabetic 
control (Two-way ANOVA followed by Bonferroni post test).
  Table 1 shows the level of plasma lipid profile such 
as triglyeride (TG), total cholesterol (TC), high density 
lipoprotein (HDL), and low density lipoprotein (LDL). Plasma 
TG, TC, and LDL level were significantly elevated and HDL 
level was decreased in diabetic rats when compared with 
control rats. Treatment with AAL reversed the diabetes 
induced hyperlipidemia. A significant reduction  of TG, TC, 
LDL(P<0.001) and increase in  HDL level was observed after 
the treatment with AAL(P<0.01).
  Effect of AAL on body weight and liver glycogen is shown 
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in Table 2. The body weight of the diabetic rats showed 
significant reduction after the administration of STZ-
nicotinamide compared to normal control rats(P<0.001). 
The treatment of diabetic rats with AAL at a dose 500 mg/
kg for two weeks showed a significant increase in body 
weight(P<0.05). The effect of AAL at 500 mg/kg dose level 
on body weight was comparable to that of glibenclamide. 
Administration of AAL at dose 500 mg/kg significantly 
increased the glycogen level which was equal to that of 
glibenclamide(P<0.001).
  There was a significant reduction of SOD, CAT and elevation 
in TBARS level were observed in diabetic rats compared to 
control animals (P<0.001). The administration of AAL (500 
mg/kg) significantly increased the SOD (P<0.05) and CAT 
(P<0.01), respectively and reduced TBARS level (P<0.01) 
(Table 3).
4. Discussion
  In the present study type 2 diabetes was induced in 
male albino rats of Charles Foster strain via single 
intraperiteoneal injection of STZ, which acts by selectively 
destroying beta cells of pancreatic islet along with 
nicotinamide, which has protective effect thus, causing only 
minor damage to cells[18]. The present study was conducted 
to assess the type 2 antidiabetic activity of AAL in STZ-
nicotinamide induced diabetic rats. The ability of AAL to 
effectively control increased blood glucose level in diabetic 
rats may be attributed to its antihyperglycemic effect as 
normoglycemic study revealed that AAL did not cause 
any reduction of blood glucose level. However, AAL was 
administered to glucose loaded normal fasted rats resulting 
in hypoglycemia which suggest that, animals treated with 
extract have better glucose utilization capacity suggesting 
its mechanism being similar to biguanides. Biguanides 
do not increase insulin secretion. They promote tissue 
glucose uptake and reduce hepatic glucose output, thereby 
producing antihyperglycemic effect and not hypoglycemic 
effect[24]. Phytochemical analysis of A. lamarckii has showed 
the presence of various classes of chemical compound viz. 
alkaloids, terpenoids, steroids, tannins, phenols etc[25]. 
Several authors reported that alkaloids, flavonoids, steroids/
terpenoids, phenolic compounds are known to be bioactive 
antidiabetic principles[26-28]. The present antidiabetic study 
of alcoholic extract may be due to synergistic effect of 
different classes of compounds. 
  DM is associated with profound alteration in the serum 
lipid and lipoprotein profile with an increased risk in 
coronary heart disease[29]. Hyperlipidemia is a recognized 
complication of DM characterized by elevated levels of 
Table 1 
Effect of AAL on lipid profile of streptozotocin-nicotinamide induced diabetic rats (mean 依 SEM, n=6).
Group Treatment TG (mg/dL) TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL)
栺 Normal control   80.70依5.43   76.53依4.82 37.94依1.00 22.44依5.43
栻 Diabetic control    160.99依5.50
△    122.38依7.99△    22.53依2.05△    67.64依7.62△
栿 D + AAL (250 mg/kg) 140.99依4.58 104.33依6.31 25.18依1.99 50.95依5.18
桇 D + AAL (500 mg/kg)     117.44依6.87**     83.99依4.90
**  32.44依2.37*    28.06依4.91**
桋 D + Gliben (10 mg/kg)     109.36依6.32**     80.62依4.78
**  34.06依1.55*    24.68依5.52**
△P<0.001 compared to normal control, * P <0.01, ** P <0.001 compared to diabetic control (One-way ANOVA followed by Tukey’s Multiple 
Comparison test).
Table 2
Effect of AAL on body weight and liver glycogen in streptozotocin-nicotinamide induced diabetic rats (mean 依 SEM, n=6). 
Group Treatment 
Body weight (g)
Liver glycogen (mg/g)
0th   Day 14th day
栺 Normal control 176.66依6.41 181.83依6.01 14.48依0.82
栻 Diabetic Control 174.16依8.07     131.16依7.12 
△       5.24依0.53 △
栿 D + AAL (250 mg/kg) 178.83依4.72  142.66依4.92    8.51依0.50
桇 D + AAL (500 mg/kg) 171.50依3.51    157.83依3.32 
*     10.77依0.39 **
桋 D + Gliben (10 mg/kg) 175.83依8.50    162.66依8.73 
*     13.40依0.82 **
△P<0.001 compared to normal control, * P <0.05, ** P <0.001 compared to diabetic control (One-way ANOVA followed by Tukey’s Multiple 
Comparison test).
Table 3 
Effect of AAL on TBARS, SOD and CAT in streptozotocin-nicotinamide induced diabetic rats (mean 依 SEM, n=6).
Group Treatment TBARS (n mol/mg protein) SOD (U/mg protein) CAT (毺 mol. H2O2  consumed/min/mg protein)
栺 Normal control 22.87依2.67 1.02依0.09 250.67依8.06
栻 Diabetic Control     52.06依4.59 
△     0.37依0.06 △       167.52依11.15 △
栿 D + AAL (250 mg/kg) 44.46依4.86 0.54依0.08   204.13依12.57
桇 D + AAL (500 mg/kg)    33.23依2.70 
**   0.71依0.07 *       225.48依10.77 **
桋 D + Gliben (10 mg/kg)    32.09依2.60 
**    0.77依0.07 *       232.00依12.28 **
△P<0.001 compared to normal control, * P <0.05, ** P <0.01 compared to diabetic control (One-way ANOVA followed by Tukey’s Multiple 
Comparison test).
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cholesterol, triglycerides and phospholipids, and changes 
in lipoprotein composition[30]. This abnormally high level 
of serum lipids is mainly due to the uninhibited actions 
of lipolytic hormones on the fat depots, mainly due to 
impairment of insulin secretion at diabetic state. Under 
normal circumstances, insulin activates the enzyme 
lipoprotein lipase, which hydrolyses triglycerides. However, 
in diabetic state, lipoprotein lipase is not activated due 
to insulin deficiency, resulting in hypertriglyceridemia 
and  insu l in  de f ic iency  i s  a l so  assoc ia ted  wi th 
hypercholesterolemia due to metabolic abnormalities[24]. 
In present study AAL significantly reduced the lipid profile 
in diabetic rats indicates its hypolipidemic activity and 
may also decrease the risk of vascular disease and related 
complications[31].
  STZ-induced diabetes is characterized by severe loss in 
body weight which was observed in the present study. AAL at 
dose level 500 mg/kg and glibenclamide administration have 
showed significant improvement in body weight (P<0.05) of 
diabetic rats when compared with untreated-diabetic ones, 
thought that AAL treated rats did not normalized the body 
weight completely. The decrease in body weight observed in 
diabetic control might be the result of protein wasting due 
to unavailability of carbohydrate for utilization as an energy 
source[32]. The treated groups enhanced glucose metabolism 
and thus, improved the body weight in STZ-diabetic rats. 
Liver play an important role in maintenance of blood 
glucose level by regulating its metabolism. The conversion 
of glucose into glycogen in liver depends on concentration of 
glucose and availability of insulin which stimulates glycogen 
synthesis, which occur in presence of enzyme glycogen 
synthase and glycogen phophorylase[33]. The reduced 
glycogen store in diabetic rats may be attributed to reduced 
activity of glycogen phosphorylase and increased activity of 
glycogen phosphorylase[34]. Treatment of diabetic rats with 
AAL and glibenclamide significantly restored the level of 
hepatic glycogen which may be due to increased secretion 
of insulin from residual pancreatic beta cells attributed to 
stimulation of glycogen synthase and inhibition of glycogen 
phosphorylase. 
  The increased concentration of lipid peroxidation due to 
hyperglycemia induces oxidative damage by increasing 
peroxy and hydroxyl radicals[35]. The increased lipid 
peroxidation in the plasma and tissues of diabetic animals 
may be due to the observed remarkable increase in the 
concentration of TBARS and MDA as a main product of lipid 
peroxidation in the plasma and liver[36-44]. Administration 
of AAL decreased significantly TBARS in treated diabetic 
rats when compared with diabetic rats. Oxidative stress in 
diabetes is associated with decrease in the antioxidant status, 
which can increase the deleterious effects of free radicals. 
The SOD and CAT are the two major scavenging enzymes 
that remove free radicals in vivo. A decrease in the activity 
of these antioxidants can lead to an excess availability 
of superoxide anion and hydrogen peroxide in biological 
systems, which generate hydroxyl radicals, resulting in 
initiation and propagation of lipid peroxidation[45]. The result 
of increased activities of SOD and CAT suggest that AAL 
contains a free radical scavenging activity. The increased 
activity of SOD accelerates dismutation of O2
•− to hydrogen 
peroxide, which is removed by catalase[46].
  In conclusion, the present study indicates that AAL have 
significant antidiabetic activity in STZ-nicotinamide 
induced diabetes. The antidiabetic activity may be due 
to improvement in glucose tolerance, restoration of liver 
glycogen and antioxidant activity of AAL can reduce the risk 
of secondary complications associated with diabetes. Further 
studies are needed to know the exact mechanism by which 
AAL bring back blood glucose towards normal level and 
bio-activity guided fractionation may unveil the constituent/
s responsible for the anti-diabetic activity of AAL.
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